BridgeMD
New treatment option for Obesity & Overweight
Official title Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans
ClinicalTrials.gov ID: NCT07506369
What this study is testing
What is Amylin (Pramlintide)?
Amylin (Pramlintide) is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for obesity & overweight.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The two pancreatic hormones amylin and pancreatic polypeptide (PP) has been linked to satiety and energy metabolism. The goal of this this study is to determine the separate and combined effects of the two hormones on food intake and other exploratory endpoints related to metabolism in healthy humans.
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65, men only. Healthy volunteers may be eligible.
You may be able to join if
- Male
- Age between 18 and 65 years at the time of inclusion
- Body mass index 18-27 kg/m2
- Fat percentage \< 20%
- Informed oral and written consent
You likely can't join if
- Anaemia (haemoglobin below normal range)
- History of hepatobiliary and/or gastrointestinal disorder(s)
- Kidney disease
- Previous gastric or intestinal resection, cholecystectomy and/or any major intra- abdominal surgery (including bariatric surgery)
- Previous pancreatic disease and/or neoplasia
- Regular tobacco smoking and/or use of other nicotine products
See the full eligibility criteria
- Male
- Age between 18 and 65 years at the time of inclusion
- Body mass index 18-27 kg/m2
- Fat percentage \< 20%
- Informed oral and written consent
- Anaemia (haemoglobin below normal range)
- History of hepatobiliary and/or gastrointestinal disorder(s)
- Kidney disease
- Previous gastric or intestinal resection, cholecystectomy and/or any major intra- abdominal surgery (including bariatric surgery)
- Previous pancreatic disease and/or neoplasia
- Regular tobacco smoking and/or use of other nicotine products
- Glycated haemoglobin (HbA1c) ≥48 and/or type 1 diabetes or type 2 diabetes requiring medical treatment
- Initiation of special diets, lifestyle changes and/or weight loss \>5% of total body weight within three months prior to or during study period
- Any physical or psychological condition or ongoing medication the investigator group suspects would interfere with trial participation
The study team makes the final eligibility decision.
Where it's taking place
- Hellerup, Capital Region, Denmark
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 18 years to 65 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hellerup, Capital Region, Denmark. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.